Anticoagulation
| The metadata subpage is missing. You can start it via filling in this form or by following the instructions that come up after clicking on the [show] link to the right. | |||
|---|---|---|---|
|
Adverse effects
Patients aged 80 years or more may be especially susceptible to bleeding complications with a rate of 13 bleeds per 100 person-years.[1]
Patients with cancer are more likely to have bleeding complications, especially if they have Stage III (regionally extensive) or IV (metastatic) cancer.[2] Regardless of the extent of cancer, the risk of bleeding was less than the risk of recurrent embolism and thromboembolism:
| No cancer | Cancer | ||||
|---|---|---|---|---|---|
| Stage I or II | Stage III | Stage IV | |||
| Major bleeding |
Events per 100 patient-years |
8.6 | 3.4 | 19.1 | 42.8 |
| Hazard ratio | 1 | 0.5 | 2.15 | 4.8 | |
| Recurrent VTE |
Events per 100 patient-years |
12.8 | 14.5 | 44.1 | 54.1 |
| Hazard ratio | 1 | 1.9 | 5.3 | 4.6 | |
| Adapted from Table 3 of Prandoni et al.[2] | |||||
References
- ↑ Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007). "Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation". Circulation 115 (21): 2689-96. DOI:10.1161/CIRCULATIONAHA.106.653048. PMID 17515465. Research Blogging. PMID 17515465
- ↑ 2.0 2.1 Prandoni P, Lensing AW, Piccioli A, et al (2002). "Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis". Blood 100 (10): 3484–8. DOI:10.1182/blood-2002-01-0108. PMID 12393647. Research Blogging.